Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Strahlen und Medizintechnik : & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services

10/11/2021 | 06:22am EST

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Expansion
Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Contract Development and Manufacturing Services

11.10.2021 / 12:20
The issuer is solely responsible for the content of this announcement.


Berlin, 11 October 2021 - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) has received from the Berlin City Government a 66-year long-term lease for an industrial property with 53,000 square feet (5,000 square meters) of factory floor located at the north eastern city limit of Berlin. The group plans to use the facility for the expansion of its contract development and manufacturing services that it provides, among others, for a variety of cancer therapeutics and radio diagnostics. Up to 10 mm EUR will be invested during the next years into the renovation of the site, the set-up of new laboratories, production and clean rooms meeting Good Manufacturing Standards for the pharmaceutical industry, and the creation of high-tech workplaces. Due to its proximity to a thermal power station, the new site is expected to meet highest energy efficiencies.

"We are encouraged to see companies in our industry developing so many exciting new radiopharmaceuticals and are eager to provide a top-tier development and manufacturing service to support their efforts", explained Dr. Lutz Helmke, COO of Eckert & Ziegler's medical division. "We may also use the site later to produce proprietary drugs and diagnostics".

The acquisition and build-up of the new facility represent a cornerstone of Eckert & Ziegler's global capacity expansion program, which is scheduled to absorb up to 100 mm EUR until the end of the decade. It will also benefit Eckert & Ziegler sites in the United States and China. Production processes developed and validated in Berlin shall be duplicated there, so that customers in the pharmaceutical industries can receive the components for their radiopharmaceuticals in an identical, standardized manner.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in industry, science, nuclear medicine and radiation therapy. The company also offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com



11.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1239745

 
End of News DGAP News Service

1239745  11.10.2021 

fncls.ssp?fn=show_t_gif&application_id=1239745&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
11/18Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
EQ
11/18Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
CI
11/16ECKERT & ZIEGLER : DZ Bank reiterates its Sell rating
MD
11/16ECKERT & ZIEGLER STRAHLEN UND MEDIZI : DZ Bank
PU
11/12Eckert & Ziegler Announces Clinical Trial Notification for Joint Clinical Trial in Japa..
EQ
11/12Eckert & Ziegler Announces Clinical Trial Notification for Joint Clinical Trial in Japa..
CI
11/09Presentation Q3/2021
PU
11/09Eckert & Ziegler Strahlen- und Medizintechnik AG Reports Earnings Results for the Nine ..
CI
11/09Quarterly Report III
PU
11/09ECKERT & ZIEGLER : One-Off Effects and Robust Operating Business Push Nine-Month Result to..
EQ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2021 180 M 203 M 203 M
Net income 2021 26,9 M 30,4 M 30,4 M
Net cash 2021 96,9 M 109 M 109 M
P/E ratio 2021 74,8x
Yield 2021 0,45%
Capitalization 2 034 M 2 302 M 2 295 M
EV / Sales 2021 10,8x
EV / Sales 2022 8,47x
Nbr of Employees 841
Free-Float 67,1%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 98,00 €
Average target price 172,00 €
Spread / Average Target 75,5%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar Löffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG118.55%2 302
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049